WILEX is a biopharmaceutical company and develops drugs based on antibodies
and small molecules with a low side effect profile and targeted treatment of
different types of cancer as well as diagnostic agents for specific detection
of tumours. WILEX’ aim is to help oncologists administer targeted treatments
to carefully diagnosed patients and to enhance patients' quality of life.
24.02.2014: Professor Olaf G. Wilhelm leaves the Executive Management Board on 31 March 2014, Dr Jan Schmidt-Brand will lead the Company.
WILEX AG today announced that Professor Olaf G. Wilhelm will step down as Chairman of the Executive Management Board when his director’s contract expires on 31 March 2014. ... More.
Seite gelesen: 113363 | Heute: 86